Pulmonary · PANCE / PANRE

Bronchiolitis (RSV)

Viral lower respiratory tract infection of infants causing wheeze, hypoxia, and dehydration.

Also known as: bronchiolitis, RSV, respiratory syncytial virus, viral bronchiolitis

Overview

Acute viral lower respiratory tract infection most common in children under 2 years, characterized by inflammation of the bronchioles producing cough, wheeze, tachypnea, and increased work of breathing. RSV causes the majority of cases.

Epidemiology

Most common lower respiratory infection in infants worldwide. Peak incidence in winter months. >2 million US outpatient visits and ~58,000-80,000 hospitalizations annually among children <5 years. Leading cause of infant hospitalization in the US.

Try two board-style Bronchiolitis questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1PulmonaryMedium
A 7-month-old presents in January with 3 days of rhinorrhea and cough, now with audible wheezing and poor feeding. Temp 38.1 C, RR 58, SpO2 94% on room air. Exam shows nasal flaring, subcostal retractions, and diffuse expiratory wheezes with scattered crackles. The infant attends daycare and has no prior respiratory episodes. Which of the following is the most likely diagnosis?
  • ACommunity-acquired pneumonia
  • BAcute bronchiolitis
  • CAcute laryngotracheobronchitis
  • DFirst episode of viral-triggered asthma
Reveal answer & full explanation
Correct answer: B — Acute bronchiolitis
  • ACommunity-acquired pneumonia
  • BAcute bronchiolitis
  • CAcute laryngotracheobronchitis
  • DFirst episode of viral-triggered asthma

Why acute bronchiolitis is correct

  • Classic acute bronchiolitis presents in an infant under 24 months in winter with a viral prodrome followed by lower respiratory signs
  • RSV infects bronchiolar epithelium, producing edema, sloughed cells, and mucus plugging of small airways, which manifests as wheezing, crackles, tachypnea, and increased work of breathing
  • The age (7 months), winter seasonality (January), daycare exposure, preceding URI, and combination of diffuse expiratory wheezes plus crackles make bronchiolitis the best fit
  • Diagnosis is clinical without need for routine imaging or viral testing

Why the others are wrong

  • Community-acquired pneumonia — Community-acquired pneumonia typically presents with focal crackles, higher fever, and a lobar infiltrate rather than diffuse wheezing in an infant with a URI prodrome
  • First episode of viral-triggered asthma — Viral-triggered asthma is not diagnosed on a first wheezing episode in an infant this young; recurrent wheezing episodes outside the bronchiolitis age window would be required
  • Acute laryngotracheobronchitis — Croup (laryngotracheobronchitis) causes inspiratory stridor and a barky cough from subglottic edema, not diffuse expiratory wheezing and crackles
Question 2PulmonaryEasy
A 4-month-old infant in January has cough, rhinorrhea, diffuse wheezing, and mild retractions. Oxygen saturation is 96% and the infant is feeding adequately. Which of the following is the most appropriate initial management?
  • ANebulized racemic epinephrine
  • BScheduled albuterol nebulizer therapy
  • CSupportive care with nasal suctioning
  • DOral amoxicillin for bacterial coverage
Reveal answer & full explanation
Correct answer: C — Supportive care with nasal suctioning
  • ANebulized racemic epinephrine
  • BScheduled albuterol nebulizer therapy
  • CSupportive care with nasal suctioning
  • DOral amoxicillin for bacterial coverage

Why Supportive care with nasal suctioning is correct

  • Mild bronchiolitis is managed with supportive care: hydration, nasal suctioning, and monitoring.
  • A well-feeding infant with 96% saturation needs no pharmacologic therapy and can be managed at home.
  • Bronchodilators, antibiotics, and corticosteroids do not improve outcomes in routine bronchiolitis.

Why the others are wrong

  • Scheduled albuterol nebulizer therapy — Asthma-transfer trap: bronchodilators are not recommended in bronchiolitis because infants lack the smooth-muscle response.
  • Oral amoxicillin for bacterial coverage — Reflex-antibiotic trap: bronchiolitis is viral, and antibiotics are reserved for a documented bacterial coinfection.
  • Nebulized racemic epinephrine — Wrong-disease trap: racemic epinephrine treats croup with stridor, not bronchiolitic wheezing with adequate saturation.
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Bronchiolitis (RSV) outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Age <2 years (peak <6 months)
  • Prematurity (<29 weeks especially)
  • Congenital heart disease (hemodynamically significant)
  • Chronic lung disease of prematurity / bronchopulmonary dysplasia
  • Immunocompromise
  • Down syndrome, neuromuscular disease
  • Daycare attendance, sibling exposure
  • Secondhand smoke exposure
  • Birth in fall/winter (first RSV season as infant)

Pathophysiology

Viral infection of bronchiolar epithelium → necrosis, sloughing, edema, mucus plugging → small-airway obstruction → ventilation-perfusion mismatch, hypoxia, hyperinflation, wheeze. Pathogens: RSV (most common, ~50-80%), rhinovirus, parainfluenza, human metapneumovirus, adenovirus, SARS-CoV-2, influenza. Coinfections common.

Clinical presentation

Symptoms

  • 1-3 days of URI symptoms (rhinorrhea, cough, low-grade fever)
  • Progression to lower respiratory tract: tachypnea, wheeze, cough, increased work of breathing
  • Poor feeding, dehydration
  • Apnea (especially in infants <2 months or preterm)
  • Symptoms peak day 3-5, resolve over 1-2 weeks

Signs / physical exam

  • Tachypnea, nasal flaring, retractions (subcostal, intercostal, suprasternal), grunting
  • Diffuse wheezes and crackles on auscultation
  • Prolonged expiration
  • Hypoxia (SpO2 <92-95% on room air)
  • Dehydration (poor PO intake), lethargy in severe cases

Differential diagnosis

  • Asthma exacerbation — Age usually >2, family history of atopy, recurrent episodes, responds to bronchodilators
  • Pneumonia — Focal consolidation on CXR, higher fever, focal exam findings
  • Foreign body aspiration — Sudden choking episode, focal wheeze, asymmetric findings
  • Congenital heart disease with heart failure — Failure to thrive, murmur, hepatomegaly, cardiomegaly on CXR
  • Anaphylaxis — Acute onset after exposure, urticaria, hypotension
  • Pertussis — Paroxysmal cough with whoop, post-tussive emesis, age extremes; PCR positive
  • Cystic fibrosis — Failure to thrive, recurrent infections, salty skin, family history; sweat chloride

Diagnostic workup

Labs

  • Clinical diagnosis — routine viral testing NOT recommended in typical cases (does not change management)
  • RSV testing may help with cohorting, public health surveillance, or when palivizumab prophylaxis decisions affected
  • Pulse oximetry to assess hypoxia
  • Consider CBC, BMP, and blood cultures only if febrile neonate (<28 days), toxic appearance, or sepsis concern (very rare bacterial coinfection)

Imaging

  • Chest radiograph NOT routinely recommended (AAP 2014) — risk of overdiagnosis of pneumonia and unnecessary antibiotics
  • Obtain CXR if focal exam findings, severe disease, fails to improve, or alternative diagnosis suspected — findings: hyperinflation, peribronchial thickening, atelectasis

Diagnostic algorithm

InterventionAAP Recommendation
Hydration and nasal suctioningSupportive — recommended
Supplemental O2 for SpO2 <90%Recommended
Routine bronchodilator (albuterol)Do not use
Systemic or inhaled corticosteroidsDo not use
AntibioticsDo not use unless bacterial coinfection
Chest physiotherapyDo not use
Routine viral testing or CXRDo not use in typical cases
Nirsevimab (prevention)Recommended for all infants <8 months entering first RSV season
AAP 2014 (and 2023 update on prophylaxis) management recommendations for bronchiolitis.

Treatment

First-line

  • Supportive care — cornerstone:
  • Suction nasal secretions (gentle bulb suction before feeds; deep suction NOT recommended)
  • Hydration: oral/NG feeds if tolerated; IV fluids if severe respiratory distress or unable to feed
  • Supplemental oxygen for SpO2 <90% (AAP 2014; lowered threshold avoids unnecessary admission)
  • Antipyretics for fever
  • Routinely AVOID (lack of benefit, possible harm):
  • Bronchodilators (albuterol, racemic epinephrine) — no proven benefit; AAP recommends against routine use
  • Systemic or inhaled corticosteroids — no benefit in viral bronchiolitis
  • Antibiotics — only if bacterial coinfection (very rare) or alternative diagnosis
  • Chest physiotherapy
  • Hypertonic saline (mixed data, modest if any benefit; not routine)

Second-line / adjunct

  • High-flow nasal cannula (HFNC) for moderate-severe hypoxia or respiratory distress
  • Nasal CPAP or BiPAP for refractory respiratory distress
  • Intubation/mechanical ventilation for impending respiratory failure
  • Admission criteria: SpO2 <90% on room air, apnea, severe respiratory distress, dehydration, inability to feed, age <3 months with significant illness, social concerns
  • Prevention:
  • Maternal RSVpreF vaccine (Abrysvo) at 32-36 weeks gestation (seasonal)
  • Nirsevimab (Beyfortus) — long-acting monoclonal antibody for all infants <8 months entering their first RSV season (and high-risk children 8-19 months), replaces seasonal palivizumab in most settings
  • Palivizumab — monthly during RSV season for high-risk infants/children when nirsevimab unavailable
  • Hand hygiene, breastfeeding, avoiding tobacco smoke and crowded settings

Complications

  • Respiratory failure requiring mechanical ventilation
  • Apnea (especially preterm and young infants)
  • Dehydration
  • Secondary bacterial infection (uncommon)
  • Post-bronchiolitis wheeze and increased asthma risk later in childhood
  • Severe RSV in immunocompromised, congenital heart disease, BPD

PANCE pearls

  • Bronchiolitis is a clinical diagnosis — routine RSV PCR, CXR, and labs are NOT recommended in typical cases (AAP 2014).
  • Bronchodilators, steroids, and antibiotics have no proven benefit in viral bronchiolitis and should be AVOIDED.
  • Nirsevimab has dramatically changed prevention — single intramuscular dose covering an entire RSV season for all infants (not just high-risk).
  • Apnea is a common and worrying complication in young infants (<2 months) and preterm infants; low threshold for admission.
  • Wheeze without prior episodes in a child <2 during RSV season = bronchiolitis; recurrent episodes after age 2 suggest asthma.

References

  • AAP 2014 — Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis (Ralston et al., Pediatrics 2014)
  • CDC/ACIP 2023 — Use of Nirsevimab for the Prevention of RSV Disease Among Infants and Young Children: Recommendations of ACIP — United States, 2023 (Jones et al., MMWR 2023)
  • MELODY Trial — Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants (Hammitt et al., NEJM 2022)
  • MATISSE Trial — Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants (Kampmann et al., NEJM 2023)

Practice Pulmonary questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.